Home › Research › Disease mechanisms
Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models
Seungmin Lee, In Gyoung Ju, Minji Lee, Jin Hee Kim, Yujin Choi, Chanmi Baek, Chan Kim, Kyuho Moon et al.. Frontiers in Pharmacology, 2026-09-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In AβO-injected mice, AR, particularly at 200 mg/kg, attenuated memory deficits, reduced hippocampal neuronal degeneration, preserved synaptic protein immunoreactivity and increased markers of hippocampal cell proliferation and immature neurons. These effects were accompanied by changes in PI3K/Akt/GSK-3β and ERK/CREB signaling, increased mature BDNF levels, and reduced cleaved caspase-3 levels. AR at 30 and 300 μg/mL protected HT22 cells and hESC-derived hippocampal neurons against AβO-induced loss of viability, while 300 μg/mL AR additionally reduced cleaved caspase-3 levels and increased inhibitory GSK-3β Ser9 phosphorylation in HT22 cells. Collectively, AR attenuated AβO-induced neuronal and synaptic injury and the associated memory impairment in acute experimental models. These findings provide promising preclinical evidence for the neuroprotective potential of AR and support its further evaluation in chronic and progressive AD models.
What this study adds
Evidence grade: Low
In mice injected with amyloid-beta oligomers and in cultured cells, Alismatis Rhizoma reduced memory deficits, neuronal degeneration and synaptic loss. The authors describe this as promising preclinical evidence and call for testing in chronic and progressive Alzheimer's disease models, so it is not yet a proven treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lee, S., Ju, I. G., Lee, M., Kim, J. H., Choi, Y., Baek, C., et al. (2026). Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1898356
Vancouver
Lee S, Ju IG, Lee M, Kim JH, Choi Y, Baek C, et al. Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models. Frontiers in Pharmacology. 2026. doi:10.3389/fphar.2026.1898356. PMID: 42761308.
BibTeX
@article{lee2026-42761308,
author = {Lee, Seungmin and Ju, In Gyoung and Lee, Minji and Kim, Jin Hee and Choi, Yujin and Baek, Chanmi and Kim, Chan and Moon, Kyuho and others},
title = {{Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models}},
journal = {Frontiers in Pharmacology},
year = {2026},
doi = {10.3389/fphar.2026.1898356},
pmid = {42761308},
url = {https://doi.org/10.3389/fphar.2026.1898356}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In AβO-injected mice, AR, particularly at 200 mg/kg, attenuated memory deficits, reduced hippocampal neuronal degeneration, preserved synaptic protein immunoreactivity and increased markers of hippocampal cell proliferation and immature neurons.
- These effects were accompanied by changes in PI3K/Akt/GSK-3β and ERK/CREB signaling, increased mature BDNF levels, and reduced cleaved caspase-3 levels.
- AR at 30 and 300 μg/mL protected HT22 cells and hESC-derived hippocampal neurons against AβO-induced loss of viability, while 300 μg/mL AR additionally reduced cleaved caspase-3 levels and increased inhibitory GSK-3β Ser9 phosphorylation in HT22 cells.
- Collectively, AR attenuated AβO-induced neuronal and synaptic injury and the associated memory impairment in acute experimental models.
- These findings provide promising preclinical evidence for the neuroprotective potential of AR and support its further evaluation in chronic and progressive AD models.
Why it matters
In mice injected with amyloid-beta oligomers and in cultured cells, Alismatis Rhizoma reduced memory deficits, neuronal degeneration and synaptic loss. The authors describe this as promising preclinical evidence and call for testing in chronic and progressive Alzheimer's disease models, so it is not yet a proven treatment.
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Pharmacology) |
| Journal's citation record | 2 / 4 | Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Myung Sook Oh: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Kyung Hee University: institution h-index 468 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42761308) |
| Free to read | 2 / 2 | Free to read |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fphar.2026.1898356
- PubMed: 42761308
- Original source →
- Free full text: Frontiers in Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.